Loading...
XJPX2183
Market cap49mUSD
Jan 17, Last price  
342.00JPY
1D
-0.29%
1Q
-10.24%
Jan 2017
-72.84%
IPO
12.13%
Name

Linical Co Ltd

Chart & Performance

D1W1MN
XJPX:2183 chart
P/E
22.84
P/S
0.63
EPS
14.98
Div Yield, %
4.09%
Shrs. gr., 5y
-0.06%
Rev. gr., 5y
1.70%
Revenues
12.31b
-1.67%
1,273,038,0002,036,005,0002,404,340,0002,512,015,0003,110,236,0003,599,236,0003,721,832,0004,872,041,0007,666,824,0008,355,754,0009,113,157,00011,313,468,00010,935,241,00010,279,314,00011,555,088,00012,516,998,00012,307,870,000
Net income
338m
-66.32%
296,584,000300,478,000273,611,000147,885,000424,199,000616,787,000449,185,000437,139,0001,330,970,0001,447,513,0001,295,994,000568,455,000482,990,000539,968,000790,487,0001,004,368,000338,266,000
CFO
1.07b
-42.08%
273,153,000161,380,000351,537,000-108,007,000613,430,000909,215,000249,212,000690,010,0001,817,153,0002,291,683,0001,360,117,000-796,810,0001,192,344,00023,610,0001,631,794,0001,839,628,0001,065,469,000
Dividend
Mar 28, 20250 JPY/sh

Profile

Linical Co., Ltd. provides drug development services primarily in the areas of oncology and central nervous system to pharmaceutical companies worldwide. The company offers drug development consulting services, such as market analysis of products in development, regulatory affairs consultation support, and licensing support. It also provides clinical research and development, and contract medical affairs services, including front-end services comprising project management, monitoring, quality control, vendor management, auditing, and clinical research secretariat; and back-end services, which include data management, bio statistical analysis, medical writing, pharmacovigilance, and medical management. The company was incorporated in 2005 and is headquartered in Osaka, Japan.
URL
https://www.linical.co.jp/
IPO date
Oct 27, 2008
Employees
759
Domiciled in
JP
Incorporated in
JP

Valuation

Title
JPY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑032023‑032022‑032021‑032020‑032019‑032018‑032017‑032016‑032015‑03
Income
Revenues
12,307,870
-1.67%
12,516,998
8.32%
11,555,088
12.41%
Cost of revenue
11,235,000
10,864,258
10,129,518
Unusual Expense (Income)
NOPBT
1,072,870
1,652,740
1,425,570
NOPBT Margin
8.72%
13.20%
12.34%
Operating Taxes
321,964
374,249
241,454
Tax Rate
30.01%
22.64%
16.94%
NOPAT
750,906
1,278,491
1,184,116
Net income
338,266
-66.32%
1,004,368
27.06%
790,487
46.40%
Dividends
(315,765)
(316,038)
(316,042)
Dividend yield
3.55%
2.01%
1.53%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
1,093,640
1,139,976
1,139,976
Long-term debt
2,109,304
2,810,832
3,395,484
Deferred revenue
Other long-term liabilities
731,381
745,668
730,674
Net debt
(4,534,446)
(3,839,292)
(2,170,158)
Cash flow
Cash from operating activities
1,065,469
1,839,628
1,631,794
CAPEX
(29,000)
(13,234)
(46,473)
Cash from investing activities
(28,000)
(14,188)
20,756
Cash from financing activities
(960,925)
(957,331)
(951,548)
FCF
857,144
1,317,594
1,676,631
Balance
Cash
7,465,192
7,042,100
5,985,618
Long term investments
272,198
748,000
720,000
Excess cash
7,121,996
7,164,250
6,127,864
Stockholders' equity
8,891,243
8,238,674
7,200,629
Invested Capital
4,742,674
4,307,096
5,018,082
ROIC
16.60%
27.42%
22.44%
ROCE
9.04%
14.41%
12.79%
EV
Common stock shares outstanding
22,586
22,586
22,586
Price
394.00
-43.47%
697.00
-23.66%
913.00
16.16%
Market cap
8,899,056
-43.47%
15,742,746
-23.66%
20,621,416
16.16%
EV
4,364,610
11,903,454
18,451,258
EBITDA
1,594,379
2,152,762
1,866,150
EV/EBITDA
2.74
5.53
9.89
Interest
17,636
12,826
14,180
Interest/NOPBT
1.64%
0.78%
0.99%